Rossari Biotech Limited reported consolidated revenue from operations of ₹6,975.60 million for the quarter ended September 30, 2026, marking a 19.01% year-on-year increase from ₹5,861.07 million in the corresponding period last year.

Profit after tax stood at ₹389.07 million, up 5.51% YoY from ₹368.76 million. The company’s basic earnings per share rose to ₹7.02 from ₹6.66 in Q2FY26. On a sequential basis, revenue remained nearly flat compared to ₹6,972.00 million in Q1FY27, while profit after tax expanded by 10.86% from ₹350.95 million.

Board Approves KSA Land Lease

In a strategic move to expand its global footprint, the Board of Directors approved the leasing of land by Rossari International Company Limited, a wholly owned subsidiary, for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). This approval follows an earlier intimation dated January 17, 2026. The detailed project plan, including the nature of the project and overall investment, will be placed before the Board for final approval once finalized.

Financial Performance Overview

The following table summarizes key consolidated financial metrics for Q2FY27:

What the Numbers Show

A divergence is visible between top-line growth and bottom-line performance. While consolidated revenue grew 19.01% YoY, profit before tax declined marginally by 0.81% YoY. This compression in pre-tax profitability occurred despite a reduction in cost of materials consumed as a percentage of revenue (from 69.47% in Q2FY26 to 68.18% in Q2FY27). The primary driver for this flat-to-negative PBT movement appears to be higher depreciation and amortization expenses, which surged 65.06% YoY to ₹300.96 million, alongside a 42.46% rise in finance costs to ₹86.77 million. These increases offset the gains from improved gross margins and lower tax expenses.

Balance Sheet and Cash Flow Highlights

Consolidated total assets increased to ₹23,594.63 million as of September 30, 2026, from ₹22,887.92 million on March 31, 2026. Cash and cash equivalents grew to ₹844.44 million, reflecting a net increase of ₹95.11 million during the half-year period. Net cash generated from operating activities stood at ₹1,314.23 million for H1FY27, a significant improvement from negative ₹250.32 million in H1FY26, driven largely by favorable working capital changes and higher operating profits.

Rossari Biotech Limited will participate in the Anand Rathi Annual Flagship Conference G-200 Summit 2026 on Tuesday, September 22, 2026. The event will feature one-on-one and group discussions with investors and analysts.

The company disclosed the schedule pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting is scheduled to begin at 2:00 pm IST in Mumbai.

Meeting Details

The discussions will focus on financial and other information already available to the public. This includes data covered in the earnings presentation submitted to stock exchanges on July 19, 2026.

Key Notes

• The date and time are subject to change due to exigencies.
• No unpublished price-sensitive information will be shared during the meeting.

Parul Gupta, Company Secretary & Head - Legal, signed the intimation letter dated September 16, 2026.